panobinostat and Viremia

panobinostat has been researched along with Viremia* in 2 studies

Trials

1 trial(s) available for panobinostat and Viremia

ArticleYear
Broad activation of latent HIV-1 in vivo.
    Nature communications, 2016, 09-08, Volume: 7

    The 'shock and kill' approach to cure human immunodeficiency virus (HIV) includes transcriptional induction of latent HIV-1 proviruses using latency-reversing agents (LRAs) with targeted immunotherapy to purge infected cells. The administration of LRAs (panobinostat or vorinostat) to HIV-1-infected individuals on antiretroviral therapy induces a significant increase in cell-associated unspliced (CA-US) HIV-1 RNA from CD4(+) T cells. However, it is important to discern whether the increases in CA-US HIV-1 RNA are due to limited or broad activation of HIV-1 proviruses. Here we use single-genome sequencing to find that the RNA transcripts observed following LRA administration are genetically diverse, indicating activation of transcription from an extensive range of proviruses. Defective sequences are more frequently found in CA HIV-1 RNA than in HIV-1 DNA, which has implications for developing an accurate measure of HIV-1 reservoir size. Our findings provide insights into the effects of panobinostat and vorinostat as LRAs for latent HIV-1.

    Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Indoles; Middle Aged; Panobinostat; RNA, Viral; Viremia; Virus Latency; Vorinostat

2016

Other Studies

1 other study(ies) available for panobinostat and Viremia

ArticleYear
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Journal of virology, 2017, 05-01, Volume: 91, Issue:9

    Antiretroviral-free HIV remission requires substantial reduction of the number of latently infected cells and enhanced immune control of viremia. Latency-reversing agents (LRAs) aim to eliminate latently infected cells by increasing the rate of reactivation of HIV transcription, which exposes these cells to killing by the immune system. As LRAs are explored in clinical trials, it becomes increasingly important to assess the effect of an increased HIV reactivation rate on the decline of latently infected cells and to estimate LRA efficacy in increasing virus reactivation. However, whether the extent of HIV reactivation is a good predictor of the rate of decline of the number of latently infected cells is dependent on a number of factors. Our modeling shows that the mechanisms of maintenance and clearance of the reservoir, the life span of cells with reactivated HIV, and other factors may significantly impact the relationship between measures of HIV reactivation and the decline in the number of latently infected cells. The usual measures of HIV reactivation are the increase in cell-associated HIV RNA (CA RNA) and/or plasma HIV RNA soon after administration. We analyze two recent studies where CA RNA was used to estimate the impact of two novel LRAs, panobinostat and romidepsin. Both drugs increased the CA RNA level 3- to 4-fold in clinical trials. However, cells with panobinostat-reactivated HIV appeared long-lived (half-life > 1 month), suggesting that the HIV reactivation rate increased by approximately 8%. With romidepsin, the life span of cells that reactivated HIV was short (2 days), suggesting that the HIV reactivation rate may have doubled under treatment.

    Topics: Anti-HIV Agents; Depsipeptides; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Indoles; Models, Theoretical; Panobinostat; RNA, Viral; Transcription, Genetic; Viremia; Virus Activation; Virus Latency

2017